Abstract
The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic neurotransmitter activity has been proposed to contribute to the manic and depressive episodes typical of these disorders. Neuropharmacological studies into the effects of cholinergic agonists and antagonists on mood state have provided considerable support for this hypothesis. Furthermore, recent clinical studies have shown that the pan-CHRM antagonist, scopolamine, produces rapid-acting antidepressant effects in individuals with either major depressive disorder (MDD) or bipolar disorder (BPD), such as bipolar depression, contrasting the delayed therapeutic response of conventional mood stabilisers and antidepressants. This review presents recent data from neuroimaging, post-mortem and genetic studies supporting the involvement of muscarinic cholinergic receptors (CHRMs), particularly CHRM2, in the pathophysiology of MDD and BPD. Thus, novel drugs that selectively target CHRMs with negligible effects in the peripheral nervous system might produce more rapid and robust clinical improvement in patients with BPD and MDD.
Keywords: Bipolar disorder, cholinergic system, CHRM2, major depressive disorder, mood disorders, muscarinic receptors.
Graphical Abstract
Current Neuropharmacology
Title:The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
Volume: 13 Issue: 6
Author(s): Won Je Jeon, Brian Dean, Elizabeth Scarr and Andrew Gibbons
Affiliation:
Keywords: Bipolar disorder, cholinergic system, CHRM2, major depressive disorder, mood disorders, muscarinic receptors.
Abstract: The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic neurotransmitter activity has been proposed to contribute to the manic and depressive episodes typical of these disorders. Neuropharmacological studies into the effects of cholinergic agonists and antagonists on mood state have provided considerable support for this hypothesis. Furthermore, recent clinical studies have shown that the pan-CHRM antagonist, scopolamine, produces rapid-acting antidepressant effects in individuals with either major depressive disorder (MDD) or bipolar disorder (BPD), such as bipolar depression, contrasting the delayed therapeutic response of conventional mood stabilisers and antidepressants. This review presents recent data from neuroimaging, post-mortem and genetic studies supporting the involvement of muscarinic cholinergic receptors (CHRMs), particularly CHRM2, in the pathophysiology of MDD and BPD. Thus, novel drugs that selectively target CHRMs with negligible effects in the peripheral nervous system might produce more rapid and robust clinical improvement in patients with BPD and MDD.
Export Options
About this article
Cite this article as:
Je Jeon Won, Dean Brian, Scarr Elizabeth and Gibbons Andrew, The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?, Current Neuropharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570159X13666150612230045
DOI https://dx.doi.org/10.2174/1570159X13666150612230045 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
UKPDS Risk Engine, Decode and Diabetes PHD Models for the Estimation of Cardiovascular Risk in Patients with Diabetes
Current Diabetes Reviews Relationship between SNP rs1764391 and Susceptibility, Risk Factors, Gene-environment Interactions of Acute Myocardial Infarction in Guangxi Han Chinese Population
Current Pharmaceutical Biotechnology Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Comparative Pharmacokinetics and Metabolism Studies in Lean and Diet- Induced Obese Mice: An Animal Efficacy Model for 11β -Hydroxysteroid Dehydrogenase Type 1 (11β -HSD1) Inhibitors
Drug Metabolism Letters Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Tartaric Acid Enhances Adrenergic Receptor Activity: Test of a General Theory of Extracellular Aminergic GPCR Enhancer Discovery
Current Drug Discovery Technologies Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Hydroethanolic Extract of <i>Lampaya Medicinalis</i> Phil. (<i>Verbenaceae</i>) Decreases Proinflammatory Marker Expression in Palmitic Acid-exposed Macrophages
Endocrine, Metabolic & Immune Disorders - Drug Targets Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design IL-1 Cytokines in Cardiovascular Disease: Diagnostic, Prognostic and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry The Roles of Abnormal Renal Sodium Handling in Hypertension Associated with Metabolic Syndrome
Current Hypertension Reviews Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomedical Applications of Poly(Lactic Acid)
Recent Patents on Regenerative Medicine New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced Acute Myocardial Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews